MuriGen’s focus is in inflammatory diseases, cancer, thrombocytopenia, epilepsy and thalassemia.

MuriGen’s lead development programs include G-CSF as a potential therapeutic target in inflammatory joint diseases, such as Arthritis. This major discovery provides a rationale for the development of G-CSF antagonists for the treatment of Arthritis and other inflammatory diseases. MuriGen is also developing a small molecule therapeutic for thrombocytopenia and cancer.